Fusion Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Fusion Pharmaceuticals

16/03/2023 12:35

* Fusion Pharmaceuticals Inc  FUSN.OQ  reported a quarterly
adjusted loss of 55 cents​​ per share for the quarter ended in
December. The mean expectation of ten analysts for the quarter
was for a loss of 56 cents per share.
    * Revenue fell 76.4% to $140.00 thousand from a year ago;
analysts
expected $17.00 thousand. 
    * Fusion Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 55 cents​.
    * The mean earnings estimate of analysts had fallen by
about 0.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Fusion Pharmaceuticals Inc shares had risen by 33.3% this
quarter.
    * The company reported a quarterly loss of $24.62 million.
    * Wall Street's median 12-month price target for Fusion
Pharmaceuticals Inc is $12.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 16 at 12:35 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.56          -0.55          Beat
 Sep. 30 2022      -0.50          -0.55          Missed
 Jun. 30 2022      -0.53          -0.44          Beat
 Mar. 31 2022      -0.48          -0.46          Beat